Friday, November 05, 2021 9:51:43 AM
Scripts for week ending October 29, 2021
Overall drug TRx -1.0% w/w
Vascepa
TRx 77,615; -4.0% (-3,260) w/w; -17.0% y/y
NRx 34,840; -4.5% (-1,623) w/w; -19.2% y/y
Ref 42,775; -3.7% (-1,637) w/w; -15.1% y/y
Lovaza (Generic & Brand)
TRx 62,471; -0.5% (-308) w/w; -1.1% y/y
NRx 30,450; -1.0% (-298) w/w; -7.3% y/y
Ref 32,021; -0.0% (-10) w/w; +5.7% y/y
Generic Vascepa
TRx 21,149; +2.5% (+517) w/w; As % of total V: 21.4%
NRx 12,116; +2.4% (+287) w/w; As % of total V: 25.8%
Ref 9,034; +2.6% (+230) w/w; As % of total V: 17.4%
Generic Vascepa by Manufacturer
Hikma - TRx 12,555 (-247); Generic share 59.4%; Total V share 12.7%
Reddy - TRx 8,594 (+764); Generic share 40.6%; Total V share 8.7%
TRx Vascepa + Generic Vascepa
TRx 98,764; -2.7% (-2,743)
NRx 46,956; -2.8% (-1,337)
Ref 51,808; -2.6% (-1,407)
Overall drug TRx -1.0% w/w
Vascepa
TRx 77,615; -4.0% (-3,260) w/w; -17.0% y/y
NRx 34,840; -4.5% (-1,623) w/w; -19.2% y/y
Ref 42,775; -3.7% (-1,637) w/w; -15.1% y/y
Lovaza (Generic & Brand)
TRx 62,471; -0.5% (-308) w/w; -1.1% y/y
NRx 30,450; -1.0% (-298) w/w; -7.3% y/y
Ref 32,021; -0.0% (-10) w/w; +5.7% y/y
Generic Vascepa
TRx 21,149; +2.5% (+517) w/w; As % of total V: 21.4%
NRx 12,116; +2.4% (+287) w/w; As % of total V: 25.8%
Ref 9,034; +2.6% (+230) w/w; As % of total V: 17.4%
Generic Vascepa by Manufacturer
Hikma - TRx 12,555 (-247); Generic share 59.4%; Total V share 12.7%
Reddy - TRx 8,594 (+764); Generic share 40.6%; Total V share 8.7%
TRx Vascepa + Generic Vascepa
TRx 98,764; -2.7% (-2,743)
NRx 46,956; -2.8% (-1,337)
Ref 51,808; -2.6% (-1,407)
Recent AMRN News
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
